Who are Fluanxol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lastacaft, Xyzal, Elestat, Rupax, Zaditor, Mizollen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flupentixol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fluanxol — Competitive Intelligence Brief

Fluanxol (FLUPENTIXOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: High Risk QT Prolonging Agents. Area: Neuroscience.

discontinued High Risk QT Prolonging Agents Histamine H1 receptor Neuroscience Live · refreshed every 30 min

Target snapshot

Fluanxol (FLUPENTIXOL). Flupentixol works by blocking the histamine H1 receptor, which helps regulate various physiological processes including mood and cognition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluanxol TARGET	FLUPENTIXOL		discontinued	High Risk QT Prolonging Agents	Histamine H1 receptor
Lastacaft	ALCAFTADINE	AbbVie	marketed	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Elestat	EPINASTINE	AbbVie	marketed	Adrenergic Receptor Agonist	Histamine H1 receptor	2003-01-01
Rupax	RUPATADINE	Teikoku Seiyaku	marketed	rupatadine	Histamine H1 receptor	2001-01-01
Zaditor	KETOTIFEN		marketed	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1999-01-01
Mizollen	MIZOLASTINE	Sanofi	marketed	mizolastine	Histamine H1 receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (High Risk QT Prolonging Agents class)

· 8 drugs in this class
Cephalon · 1 drug in this class
Pfizer · 1 drug in this class
Roxane · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluanxol — Competitive Intelligence Brief. https://druglandscape.com/ci/flupentixol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab